The Safety and Effectiveness of (+)-Calanolide A in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs
- Conditions
- HIV Infections
- Registration Number
- NCT00005120
- Lead Sponsor
- Sarawak MediChem Pharmaceuticals
- Brief Summary
The purpose of this study is to see if it is safe and effective to give calanolide A to HIV-infected adults who have not used anti-HIV drugs in the past.
- Detailed Description
Patients are randomized to receive (+)-calanolide A or placebo for 21 days. All patients may elect to receive an open-label, 3-month course of approved retroviral therapy (up to triple-drug therapy) to be selected by, and administered under the care of, the patients' physicians. If the patient has no insurance coverage or does not wish to utilize his/her insurance for anti-HIV medications, Sarawak MediChem Pharmaceuticals will provide these medications at no charge for up to 3 months.
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 16
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (6)
South Florida Bioavailability Clinic
🇺🇸Miami, Florida, United States
Chicago Ctr for Clinical Research
🇺🇸Chicago, Illinois, United States
The CORE Ctr
🇺🇸Chicago, Illinois, United States
Anderson Clinical Research
🇺🇸Pittsburgh, Pennsylvania, United States
Burnside Clinic
🇺🇸Columbia, South Carolina, United States
Univ of Texas Med Branch
🇺🇸Galveston, Texas, United States
South Florida Bioavailability Clinic🇺🇸Miami, Florida, United States